We constructed a melanoma-specific oncolytic adenoviral vector Ad.MCDIRESE1.71Hsp3, in which the cytosine deaminase and adenoviral E1A genes linked by the IRES sequence were under the control of a mouse tyrosinase enhancer/promoter transcriptional element in the E1 region of the vector. We also inserted the human heat shock protein 70 (Hsp70) gene driven by the cytomegalovirus promoter into the E3 region of this vector. The RGD-4C peptide was inserted into the HI loop of the fiber knob domain of the Ad.MCDIRESE1.71Hsp3 vector to increase the transduction efficiency of this vector to tumor cells. The Ad.MCDIRE-SE1.71Hsp3 vector replicates specifically in melanoma cells, and it has a melanoma-specific cytotoxic effect in the presence of 5-fluorocytosine in vitro and in vivo. Moreover, the in vivo killing of tumor cells associated with the overexpression of Hsp70 generated by the intratumoral injection of the Ad.MCDIRESE1.71Hsp3 vector into established subcutaneous tumors can lead to the suppression of tumor growth and potent melanoma-specific systemic immune responses.
Introduction
The experiments summarized in this paper show that the Ad.MCDIRESE1.71HSP3 adenoviral vector, which is designed to be cytolytic on the basis of melanomaspecific expression of E1A and the cytosine deaminase (CD) gene, and binds more selectively tumor cells than normal cells by addition of the RGD peptide to the fiber, can also be engineered to induce a tumor-specific immune response through insertion of a transcription unit for the Heat Shock 70 gene.
The heat shock 70 protein (Hsp70) belongs to a family of chaperone proteins that prevent apoptosis, promote functional folding of newly synthesized proteins, facilitate the transport of peptides throughout the cell, and activate innate and adaptive immune responses. 1 The innate immune responses induced by heat shock proteins (HSPs) include: (1) cytokine and chemokine release by antigen-presenting cells (APCs) and T cells; (2) maturation of dendritic cells (DCs) by upregulating the expression of costimulatory and antigen-presenting molecules such as B7-1, B7-2 and major histocompatibility complex (MHC) class II molecules; (3) induction of migration of DCs to draining lymph nodes; and (4) activation of natural killer (NK) and other immune cells. 2 Heat shock proteins can also function as cytokines that attract DCs and T cells to tumors. 3 Tumor cells harbor a unique repertoire of mutated antigens that could potentially induce a tumor-specific immune response. However, tumor cells are generally incapable by themselves of provoking an effective immune response, partly owing to the inadequate antigen presentation or dysfunctional interactions with professional APCs such as DCs. 4 Heat shock proteins have the ability to chaperone and present a variety of tumor antigens to DCs. Heat shock proteins form complexes with antigenic peptides and then gain access to the MHC class I and class II antigen-processing pathways in DCs via HSP receptor (such as CD91)-mediated uptake, which promotes CD8+ and CD4+ T-cell responses. 5 Vaccination with HSPs isolated from cancer cells has been shown to elicit a tumor-specific immunity, such as the induction of cytotoxic T-lymphocyte (CTL) responses in vitro against a variety of antigens expressed in the cells from which HSP/antigenic complexes have been purified. 6, 7 The specificity of the induced CTLs relies on the peptides chaperoned by these HSPs. 8 Generally, effective cancer vaccine strategies promote tumor antigen release in the context of potent inflammatory signals. These signals activate and induce the maturation of APCs, which then present epitopes to T cells in an activating, rather than a tolerogenic manner. 9 One of the most effective ways to stimulate antitumor immunity has been to express genes that promote the cross-priming of host APCs by enhancing either direct release of tumor antigens from tumor cells in vivo or recruitment and activation of APCs. In this regard, killing tumor cells in vivo with the herpes simplex virus thymidine kinase/gancyclovir (HSV tk/GCV) system or with the CD/5-fluorocytosine (5-FC) system, associated with the expression of stress proteins, such as Hsp70, can lead to potent immunogenicity against released tumorassociated antigens. 10, 11 Cytosine deaminase catalyzes the conversion of the inactive non-toxic precursor drug, 5-FC into the toxic chemotherapeutic agent 5-fluorouracil (5-FU).
We chose to use oncolytic adenoviral vectors because they have been shown to induce high expression levels of therapeutic genes and directly kill tumor cells by specific replication in tumor cells. Such vectors that replicate selectively in tumor cells can be obtained either by the mutation of viral replication genes, which can be complemented by helper functions present in tumor cells, 12, 13 or by using tumor-specific promoters that drive critical viral genes so that they can be expressed only in tumor cells.
14 Moreover, the introduction of suicide genes into oncolytic adenoviral vectors produces a therapeutic tumor suppressive effect, which is greater than vectors with either viral replication genes or suicide genes alone. 15, 16 We proposed that the specific killing of tumor cells in vivo by an adenoviral vector that can both replicate and induce the expression of a chemotherapy sensitization gene in a tumor-specific manner along with the overexpression of HSP in tumor tissue, may increase the availability of tumor-associated antigens to APCs in a ready-to-be-processed form. These antigens are usually immunologically hidden in growing tumors. We constructed a melanoma-specific oncolytic adenoviral vector Ad.MCDIRESE1.71Hsp3 that has the following properties: first, this vector replicates and induces the expression of CD gene specifically in melanoma cells. Second, this vector contains the Hsp70 expression cassette in the E3 region, and is designed to allow induction of overexpression of Hsp70 in infected cells or tumor tissues. Third, an RGD-4C peptide is presented in the HI loop of the vector and increases the infection efficiency of this vector to tumor cells. This Hsp70-armed vector is one step beyond other tumor-specific cytolytic vectors reported in the past that carried a combination of tumor-specific E1A and CD transcription units along with a tumor-targeted fiber protein. Our experiments show that the in vivo killing of tumor cells associated with overexpression of Hsp70 generated by the intratumoral injection of the Ad.MCDIRESE1.71Hsp3 vector into established subcutaneous tumors can lead to the suppression of tumor growth and to a potent melanoma-specific systemic immune response.
Results

Construction of adenoviral vectors
We assembled the MTE4TP construct, which is designed to be specific for cells capable of melanin synthesis by linking four mouse tyrosinase enhancers (MTEs) and connected that enhancer cassette to one mouse tyrosinase promoter (MTP). We found that this MTE4TP promoter/ enhancer cassette generated higher transcriptional activity of transgenes that it directs in human and mouse melanoma cell lines compared with constructs that contained two MTEs linked with one MTP (data not shown). The MTE4TP promoter produced levels of gene expression in melanoma cells that were much higher than those seen in non-melanin producing tumor cells of other epigenotypes. We decided to use the MTE4TP transcriptional regulatory element in the construction of adenoviral vectors.
Some of the control vectors (Ad.CMV-Luc(RGD), Ad.CMV-CD(RGD) and Ad.MCDIRESLuc1Hsp3) were replication-deficient vectors. The luciferase gene was driven by the CMV promoter in the Ad.CMV-Luc(RGD) vector. The bacterial CD gene was driven by the cytomegalovirus (CMV) promoter in the Ad.CMV-CD(RGD) vector. The CD gene and luciferase gene linked by internal ribosomal entry site (IRES) sequence followed by SV40 poly(A) were driven by the MTE4TP element in the E1 region of the Ad.MCDIRESLuc1Hsp3 vector, which also contained the CMV-Hsp70/poly(A) expression cassette in the E3 region.
We also assembled conditionally replication-competent adenoviral vectors. These vectors (Ad.MCDIRESE1.71Luc3 and Ad.MCDIRESE1.71Hsp3) are E1B 55 kDa-deleted conditionally replication-competent adenoviral vectors in which the E1A gene from bases 541 to 2265 and the CD gene linked by IRES were driven by the MTE4TP element in the E1 region. The replication competency of these vectors will be observed in cells that are capable of producing melanin through expression of the tyrosinase gene. The CMV-Luc/poly(A) cassette was inserted into the E3 region of the Ad.MCDIRESE1.71Luc3 vector. The CMV-Hsp/poly(A) cassette was inserted into the E3 region of the Ad.MCDIRESE1.71Hsp3 vector. The RGD-4C ligand was inserted into the HI loop of all of the vectors. This design was based on previous published experiments from our laboratory 21 and those of others in which the insertion of the RGD peptide into the H1 loop of the fiber protein increased the level of infection of tumor cell lines. Tumor cell lines are often observed to have a level of CAR receptors on the plasma membrane which is much lower than that found on the plasma membrane of normal cells.
A synthetic poly(A) sequence was inserted downstream of the left hand ITR to avoid nonspecific gene expression induced by the ITR in three of the five vectors. The structural organization of each of these vectors is shown in Figure 1 . The absence of the Ad5 wild-type virus in each vector preparation was confirmed by polymerase chain reaction (PCR) (data not shown). Ad.CMV-Luc(RGD)
Ad.CMV-CD(RGD) 
71Hsp3 vectors in cell lines
To test the in vitro cytotoxic effect of different vectors, we exposed the MeWo, HeLa, B16 and LLC cell lines to the Ad5 virus, and to the Ad.MCDIRESLuc1Hsp3, Ad.MCDIRESE1.71Luc3, Ad.MCDIRESE1.71Hsp3 or to To test whether intratumoral injection of Ad.MCDIR-ESE1.71Hsp3 vector plus intraperitoneal injection of 5-FC could induce a systemic immune response, we carried out an immunization-rechallenge experiment. B16-bearing mice from different treatment groups were rechallenged with B16 cells on the left flank 7 days after the first intratumoral injection of the right flank subcutaneous tumors with the vectors. As shown in Figure 5c , 3 weeks after rechallenge, five of the seven mice that had received the Ad.MCDIRESE1.71Hsp3 vector plus 5-FC The survival of cells was measured by 3(4,5-Dimethylthiazol-2yl)2,5diphenyltetrazolium bromide (MTT) assay 7 days later. The data represents the average of two determinations. 
Tumor-specific cytotoxic T-lymphocyte responses induced by the Ad.MCDIRESE1.71Hsp3 vector plus 5-FC
The above data suggest that the injection of the Ad.MCIRESE1A.71Hsp3 vectors is inducing a systemic antitumor immune response. Because HSP vectors have been reported to induce an immune response, 12 and tumor damage has been shown to increase the level of the immune response induced by adenoviral vector vaccines, we evaluated the cytolytic activity of splenocytes from vector-treated B16 tumor-bearing mice to target tumor cells using lactate dehydrogenase assay. Splenocytes from B16-bearing mice treated with the Ad.MCDIRESE1.71Luc3 plus 5-FC, with the Ad.MCDIR-ESE1.71Hsp3 plus 5-FC or without 5-FC, or with PBS, were obtained 12 days after the injection of the vector. These cells were re-stimulated in vitro by co-culture with mitomycin C-treated B16 cells as effector cells. As shown in Figure 6a and b, spleen cells from the Ad.MCDIR-ESE1.71Hsp3 vector plus 5-FC-treated mice were cytotoxic against B16 cells whereas spleen cells from the mice 
Discussion
Other workers have reported the induction of a potent antitumor immune response through the combination of tumor killing by activation of a suicide gene to release tumor antigens and in situ Hsp70 overexpression to enhance DC antigen presentation. 17 One of these experiments used a replication-deficient adenoviral vector in which the CMV promoter drove the Hsp70 gene and the TK gene. This vector strategy which relies on non-tissuespecific expression of the TK gene, could lead to damage in the normal tissues. To prevent this potential complication, we constructed a melanoma-specific oncolytic adenoviral vector Ad.MCDIRESE1.71Hsp3 in which the Ad5 E1A gene from bases 541-2265 with translation stop codons was driven by the melanoma-specific MTE4TP transcriptional regulatory element.
The melanoma-specific expression of the Ad5 E1A gene not only allows the viral vector replicate in melanoma cells, but also induce immune-mediated cell killing. 18 As expected, the Ad.MCDIRESE1.71Hsp3 vector replicated in human melanoma cells (see Figure 4) . However, this vector did not replicate as well as wildtype adenovirus in human melanoma cells (see Figure 4) . This may be due in part to the limited expression of the MTE4TP-regulated E1A as compared with the E1A controlled by the wild-type adenovirus early promoter (see Figure 3) .
The CD prodrug transcriptional unit was also inserted into the oncolytic Ad.MCDIRESE1.71Hsp3 vector so that its expression is specific for tumor cells that express tyrosinase. The CD gene is a bacterial gene that converts 5-FC, a non-toxic precursor, into the active and toxic chemotherapy agent, 5-FU. 19 The rate of conversion of the 5-FC to the 5-FU catalyzed by CD is so efficient, that the levels of 5-FU exceed the ability of the ATPdependent kinases to phosphorylate all of the 5-FU. Very large quantities of unphosphorylated 5-FU are therefore produced in the CD vector infected cells which can pass through the plasma membrane of the cell by diffusion. This 5-FU is then taken up by surrounding uninfected cells, leading to the death of these uninfected cells. This is called the bystander effect. The levels of 5-FU generated in these cells (in the 300 mM range) are so high that even non-dividing cells die due to inhibition of protein translation. 20 The infection of cells with the Ad.MCDIRESE1.71Hsp3 vector followed by addition of 5-FC generated melanoma-specific cytotoxic effects in vitro (Table 2) .
To overexpress the Hsp70, the CMV-Hsp70/SV40 poly(A) was inserted into the E3 region of the Ad.MCDIRESE1.71Hsp3 vector. As the Hsp70 protein is not directly injurious to normal cells, we could use the CMV promoter. High levels of the Hsp70 protein are required as the mechanism of action of the Hsp70 protein is stoichiometric, not catalytic, as is the case with the CD gene. Indeed, the expression level of Hsp70 increased 11-30-fold in cell lines infected with the Ad.MCDIR-ESE1.71Hsp3 vector as compared with that of cell lines infected with the Ad5 (Table 1 ). The insertion of the Hsp70 expression cassette into the E3 region of the same vector did not affect the replicative ability of the vector (see Figure 4) , although the expression of the Hsp70 may have prolonged the time required for generating adenoviral vectors in the 293 packaging cell lines (unpublished data). Moreover, an RGD-4C was inserted into the HI loop of the Ad.MCDIRESE1.71Hsp3 vector to increase the transduction efficiency of adenoviral vector to tumor cells. Previous experiments in our laboratory had suggested that the RGD modification of the fiber protein would increase the infection efficiency of these vectors for tumor cells. 21 The intratumoral injection of the Ad.MCDIRE-SE1.71Hsp3 vector plus intraperitoneal injection of the 5-FC suppressed the in vivo growth of the subcutaneous B16 tumors in immunocompetent mice. The suppression effect is melanoma-specific (see Figure 5) , and the CTL responses thereby generated (see Figure 6 ) may have contributed to this suppressive effect. Moreover, overexpression of Hsp70 in tumor tissue when used alone, or the CD/5-FC-mediated tumor cell killing when used alone was insufficient to induce spleen cells which were cytotoxic to tumor cells in vivo (Figure 6a ). These results are consistent with the conclusion of previous reports from other laboratories, 17 which indicated that both the killing tumor cells in vivo to release tumor-specific antigen and the overexpression of Hsp70 to facilitate the antigen-presentation by APCs are essential to provoke systemic immune responses for tumor cells. The induction of a tumor cell immune response by the intratumoral injection of the vector carrying the CD, E1A and Hsp70 transcription units may arise from the increased delivery of tumor associated antigens that comes from the combined effect of tumor cell destruction owing to the CD and E1A genes, and the chaperone effect of the Hsp70 protein.
In summary, the Ad.MCDIRESE1.71Hsp3 vector we constructed can suppress tumor growth and induce potent melanoma-specific immune responses. Moreover, we can use this strategy for many different tumor types by using different tumor-specific promoters to drive the expression of the therapeutic transcription units in the vectors.
Materials and methods
Cell lines
The human embryonic kidney 293 cell, human melanoma cell lines SK-Mel-28, MeWo, human cervical carcinoma cell line HeLa, mouse melanoma cell line B16, mouse LLC were purchased from American Type Culture 
Recombinant adenoviral vectors
Human heat shock protein 70 (Hsp70) gene was obtained by PCR from plasmid pH2.3 (ATCC). The CMV promoter was obtained by PCR from pShuttle-CMV 22 plasmid. The CMVHSP70 DNA fragment, which contained the Hsp70 gene driven by CMV promoter and followed by SV40 poly(A), was inserted into the pAd.PmeI/SalI(R) vector. 23 The plasmid generated was named pAd.Hsp. Plasmid pAd.Luc was generated by inserting the CMVLuc DNA fragment which contained the luciferase gene driven by CMV promoter and followed by SV40 poly(A) sequence into the pAd.PmeI/SalI(R) vector. pAd.Hsp plasmid and pAd.Luc plasmid contained the same sequence as pAdeasy-1 plasmid, 22 except for two modifications. First, an additional RGD-4C sequence was inserted into the HI loop. Second, a Hsp70 gene or luciferase gene which was driven by CMV promoter and followed by SV40 poly(A), was inserted into the E3 region.
The MTP (À815 to À45 bp relative to the mouse tyrosinase transcription start site) and the MTE (À12.1 to À12.3 kb upstream of the mouse tyrosinase transcription start site) were obtained by PCR from B16 mouse melanoma cells. MTE4TP was a construct containing four MTEs linked to one MTP. DNA fragment MCDIRESLuc, which contained the CD gene and the luciferase gene linked by an IRES sequence, driven by the MTE4TP and followed by SV40 poly(A), was inserted into the pShuttle plasmid. 22 The plasmid generated was named pShuttleMCDIRESLuc.
The Ad E1A gene from bases 541 to 2265 was generated by PCR from pShuttleAd.Tyr-E1A vector 21 by a pair of primers (primer 1: 5 0 -CTAGTCTAGACATAT GTCCGACACCGGGAC-3 0 , primer 2: 5 0 -GGAATTCCA TATGTTAAGCCACCTATACAACATTC-3 0 ). The resultant DNA fragment E1.7 contained two mutations (in boldface and underline) at bases 2252 (C-T) and 2262 (G-T), generating premature translation stop codons in the 55-kDa E1B reading frame at codons 79 and 82 according to the method described by Huang et al.
5 DNA fragment MCDIRESE1.7 contained the CD gene and the E1.7 fragment linked by an IRES sequence, driven by the MTE4TP and followed by SV40 poly(A). Plasmid pShuttleMCDIRESE1.7 was generated by inserting the MCDIRESE1.7 fragment into the pShuttle plasmid.
The Ad.MCDIRESE1.71Hsp3 and Ad.MCDIRESLuc1Hsp3 vector were obtained by homologous recombination between the pShuttleMCDIRESE1.7 or the pShuttleMCDIRESLuc plasmid and the pAd.Hsp plasmid, followed by PacI digestion and transfection into 293 cells. The Ad.MCDIRESE1.71Luc3 vector was obtained by homologous recombinant between the pShuttle-MCDIRESE1.7 plasmid and the pAd.Luc plasmid, followed by PacI digestion and transfection. The Ad.CMV-Luc(RGD) and Ad.CMV-CD(RGD) vectors were constructed as described previously. 21 Human wild-type adenovirus 5 was purchased from ATCC (Manassas).
All the vectors were amplified in 293 cells and purified by CsCl 2 gradient ultracentrifugation. The titer of different vectors was tested by BD Adeno-Xt Rapid Titer Kit (BD Biosciences, Palo Alto, CA, USA). The viral DNA was isolated from purified stocks and PCR was used for detecting wild-type virus according to methods described previously. 21 Ad-mediated gene transfer assay in vitro
The Ad.CMV-Luc(RGD) and Ad.MCDIRESLuc1Hsp3 vectors were used to infect cell lines at MOI 1 or MOI 10, respectively. Cells were washed with PBS 48 h later. Luciferase activity was analyzed as before. 21 The protein concentration of the cell lysates was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA) to normalize the value of the relative light units by the protein concentration for each sample.
Western blot
MeWo and HeLa cells were plated on six-well plates and infected by the wild-type Ad5, the Ad.MCDIRESLuc1Hsp3 Ad.MCDIRESE1.71Luc3, and Ad.MCDIRE-SE1.71Hsp3 vectors at MOI 50. Forty-eight hours later, cells were harvested and immunoblotting was carried out to determine cellular E1A and human b-actin expression following the method described previously. 21 Antibody binding was visualized by enhanced chemiluminescence (Amersham Life Sciences Inc., Arlington Heights, IL, USA).
Heat shock protein quantitative assay
MeWo, B16 and LLC cells were plated on 12-well plates and infected by the wild-type Ad5, the Ad.MCDIRESLuc1Hsp3, Ad.MCDIRESE1.71Luc3 and Ad.MCDIRE-SE1.71Hsp3 vectors at MOI 50. Forty-eight hours later, cells were washed with PBS and harvested. The supernatant of cell lysates was subjected to ELISA assay (Stress Xpress Hsp70 ELISA Kit, Stressgen, Canada) for the detection and quantitation of Hsp70.
Adenoviral vector progeny production assay
MeWo and HeLa cells grown as monolayers in 12-well plates were infected with wild-type Ad5, the Ad.MCDIRESLuc1Hsp3, Ad.MCDIRESE1.71Luc3 and Ad.MCDIRESE1.71Hsp3 vectors at MOI 10. Seven days later, the cell-free supernatant medium was collected. The titer of vectors in the supernatant medium was then determined by using the BD quick titer kit on 293 cells. 
Animal experiment
Subcutaneous tumor models were established by injecting 1 Â 10 6 B16 or LLC cells into the right flank of C57BL/ 6 female mice (4-8 weeks old). When tumor sizes reached 70-80 mm 3 , mice carrying the B16 tumor were randomly divided into four groups and injected intratumorally with 50 ml of the Ad.CMV-CD(RGD), Ad.MCDIRESE1.71Luc3, the Ad.MCDIRESE1.71Hsp3 vectors (3 Â 10 8 ifu/mice) or with PBS once a day for three consecutive days. Mice carrying the LLC tumor were randomly divided into three groups and injected intratumorally with 50 ml of the Ad.CMV-CD(RGD), the Ad.MCDIRESE1.71Hsp3 vectors (3 Â 10 8 ifu/mice) or with PBS once a day for three consecutive days. Twenty-four hours after first injection, 500 mg/kg of 5-FC was injected into the peritoneal cavity each day for 7 days. Tumor growth was monitored every 2 days and the tumor volume was calculated according to the formula: tumor volume ¼ length Â width 2 /2. In the tumor challenge experiment, mice carrying the B16 tumor treatment group were rechallenged with 2 Â 10 4 B16 tumor cells in the left flank 7 days after the first injection of the vectors.
Cytotoxic T-lymphocyte assay
Twelve days after the first intratumoral injection of different vectors, mice carrying the B16 tumor were killed, splenocytes were isolated and restimulated with mitomycin C-treated B16 tumor cells for 5 days as effector cells. The ability of the effector cells to lyse target cells was determined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA) according to the manufacturer's instruction.
